Develops drug therapies for gastrointestinal diseases and disorders. The Company's commercial and therapeutic focus is in functional disorders, such as irritable bowel syndrome, non-ulcer dyspepsia , functional diarrhea and gastroparesis, acid disorders, such as gastroesophageal reflux disease and Barretts esophagus, and inflammatory diseases, such as ulcerative colitis and Crohns disease. Pharmaceutical therapies are products based on Known Molecular Entities and targeted to large chronic markets designed for the treatment of functional disorders, acid disorders and inflammatory diseases.